Eyelid myoclonus with absences (EMA) was first described by Jeavons in 1977. He fully described it as an epileptic syndrome characterized by eyelid myoclonus with transient absences, characterized by generalized symmetric electrical activity due to eye closure and photosensitivity. It has been suggested that EMA should be named “Jeavons syndrome” as a separate epilepsy syndrome within idiopathic generalized epilepsies (IGEs). The eyelid myoclonus, with or without akinetic seizures, is classified as a separate type of generalized seizure in the 2001 International Classification of Epileptic Seizures. Jeavons syndrome is characterized by episodes of brief, rapidly repetitive eyelid clonic contractions without significant loss of consciousness or only mildly impaired consciousness (with akathisia), synchronized with generalized high-amplitude 3-5 Hz spikes or spikes of short duration (1-5 seconds) on the EEG, often triggered by characteristic eye closure movements, and in fact, all patients are photosensitive. Jeavons syndrome is considered to belong to a separate syndrome in IGE and, according to previous reports, is also considered to be an idiopathic myoclonic syndrome with the main clinical feature being eyelid myoclonus, which can occur alone or progress to transient akathisia in the same patient, with epileptic seizures evoked mainly by eye closure and light stimulation. As a form of photosensitive epilepsy, patients can often self-initiate. The syndrome requires long-term antiepileptic drug therapy, with valproic acid being the first choice, followed by ethosuximide and lamotrigine. Persistent frequent epileptic seizures require add-on therapy, with valproic acid combined with ethosuximide or clonidine or lamotrigine. Clonidine is more effective for myoclonic seizures of the eyelids.